The First Web 2.0 Pharmaceutical News Portal

World Pharma News project is launching a Web 2.0 pharmaceutical news platform, named as well World Pharma News but with attached '.net' extension. Web 2.0 generally represents knowledge-oriented social-networking platforms focused first of all on collaborative approaches.

"We know that it is a very ambitious initiative but we trust in the power and in the flexibility of the coming Web 2.0 pharmaceutical solutions/interfaces, we sincerely hope that in the nearest future the term 'Pharma 2.0' will sound as well appropriate as the terms Web 2.0 or Health 2.0", assumed World Pharma News .net administrator.

World Pharma News .net, by being based on the well known open source software, is following the Web 2.0 strategy of hosting, supporting and motivating the online content submission (pharmaceutical news articles). Additionally, the launched platform looks very similar to the known Digg.com presence. The main differences are the design and in special the targeted pharmaceutical sector which makes World Pharma News .net the first worldwide Web 2.0 pharmaceutical news platform.

"All Internet users interested in the next appearance of the 'pharma' domain, called by us 'Pharma 2.0', are very welcome to explore World Phamra News .net and in special to register, submit or to vote the collected and published news articles", said project administrator.

For further information, please visit:
http://www.worldpharmanews.net

About World Pharma News .net
World Pharma News .net is an advanced Web 2.0 pharmaceutical news portal developed on the top of the World Pharma News .com Project. For further information, please visit www.worldpharmanews.net.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...